Key result
Higher baseline EPA linked to ~71% lower all-cause mortality per 1% increase after acute MI.
Why the study?
Do plasma levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) predict all-cause mortality in patients with acute myocardial infarction?
Population
508 patients with acute myocardial infarction admitted to Severance Cardiovascular Hospital in Korea.
Design
Cohort
Follow-up
mean 16.1 months
Authors
Loading...
EPA levels may refine post-AMI mortality risk stratification; leaves open whether supplementation improves outcomes in RCTs.
Cohort (n=508)
No
Do plasma levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) predict all-cause mortality in patients with acute myocardial infarction?
Hazard Ratio: 0.29 (95% CI 0.12–0.67)
p-value: p=0.004
Lower plasma levels of EPA, but not DHA, independently predict all-cause mortality in patients with acute myocardial infarction, particularly in women.
Lee et al. (2009) conducted a cohort in Acute Myocardial Infarction (n=508). Plasma phospholipid eicosapentaenoic acid (EPA) level vs. Lower EPA levels was evaluated on All-cause mortality (HR 0.29, 95% CI 0.12-0.67, p=0.004). Higher baseline plasma eicosapentaenoic acid (EPA) levels independently predicted a lower risk of all-cause mortality (HR 0.29 per 1% increase) in patients with acute myocardial infarction.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: